BreezeBio
GenEdit (now operating as BreezeBio) is a South San Francisco-based genetic medicine company developing nanoparticle delivery technology for gene therapy and gene editing applications. The company's proprietary NanoGalaxy platform provides a library of non-immunogenic nanoparticles that enable targeted delivery of genetic payloads to specific cells and tissues. GenEdit's lead program focuses on autoimmune disease and has established a multi-year collaboration with Genentech. The company rebranded to BreezeBio in 2026 to reflect its pipeline focus on autoimmune disease, including a Type 1 Diabetes program called BRZ-101.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Jan 2024
Sep 2021
Dec 2018
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
